Mankind Pharma to Acquire BSV for INR 13,630 Crores: A Strategic Move to Lead Indian Women's Health & Fertility Segment
Mankind Pharma Limited has signed a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Limited (BSV) from Advent International for an enterprise value of approx. INR 13,630 Crores. This strategic acquisition aims to position Mankind Pharma as a market leader in the Indian women's health and fertility drug market, providing access to other high entry barrier products in critical care with established complex R&D tech platforms. BSV, a biopharmaceutical leader with over five decades of experience, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities. The acquisition will add BSV's robust branded product portfolio across Women's Health, Fertility, and Critical Care to Mankind Pharma's offerings, along with a dedicated in-house R&D center, a strong product pipeline, and a diverse domestic product portfolio with niche filings across markets.
Key Highlights
- Mankind Pharma to acquire 100% stake in BSV for INR 13,630 Crores, expanding its presence in high entry barrier complex portfolios and high potential OTX brands.
- BSV brings strong R&D capabilities, a robust branded product portfolio, and a dedicated in-house R&D center with 60+ scientists to Mankind Pharma.
- BSV's product portfolio includes a comprehensive fertility drug portfolio globally and a niche portfolio offering in Women's Health, encompassing the entire lifecycle.
- The acquisition will strengthen Mankind Pharma's position in the Indian women's health and fertility segment and provide access to critical care products with complex R&D tech platforms.
- BSV's established Specialty R&D Tech Platforms align with Mankind Pharma's strategic vision to expand its footprint in high entry barrier portfolios.